Skip to main content

Table 3 Clinical characteristics of MSA patients and healthy controls in qPCR

From: Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson’s disease

  n Female Male Age, yr. (mean ± S.E.) Disease Duration, yr. (mean ± S.E.) Clinical Scale (mean ± S.E.)
  UMSARS
Part 1 Part 2 Part 3 (ΔsBP) Part 3 (ΔdBP) Part 4
MSA-C 31 16 (51.6%) 15 (48.4%) 60.72 ± 1.73 3.09 ± 0.32 16.83 ± 1.62 15.90 ± 1.69 −28.93 ± 4.25 −12.33 ± 2.62 2.04 ± 0.20
MSA-P 30 17 (56.7%) 13 (43.3%) 68.08 ± 1.31 a 3.01 ± 0.32 19.63 ± 1.69 22.30 ± 1.85 −20.56 ± 3.23 −10.33 ± 2.50 2.88 ± 0.19
  UPDRS
Part 1 Part 2 Part 3 Part 4  
PD 28 15 (53.6%) 13 (46.4%) 68.97 ± 1.32 a 9.58 ± 0.98 b 2.64 ± 0.42 12.78 ± 1.84 25.32 ± 3.40 2.12 ± 0.51  
Control 28 13 (46.4%) 15 (53.6%) 63.18 ± 1.29       
  1. MSA multiple system atrophy, PD Parkinson’s disease, UMSARS Unified Multiple System Atrophy Rating Scale, ΔsBP systolic blood pressure reduction on standing, ΔdBP diastolic blood pressure reduction on standing, S.E. standard error
  2. a Patients in the MSA-P and PD groups were significantly older than those in the MSA-C and control groups (p < 0.05)
  3. b Patients with PD had significantly longer disease duration compared to those with MSA-C and MSA-P (p < 0.05)